

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5103366

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADEL MOUSSA	02/01/2017
JEAN-PIERRE SOMMADOSSI	02/01/2017
RECEIVING PARTY DATA	
Name:	ATEA PHARMACEUTICALS, INC.
Street Address:	125 SUMMER STREET
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02110
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15885630
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6786941262
Email:	docket@kipsllc.com
Correspondent Name:	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC
Address Line 1:	400 PERIMETER CENTER TERRACE
Address Line 2:	SUITE 200
Address Line 4:	ATLANTA, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	12020-009US1
NAME OF SUBMITTER:	BRENT R. BELLOWS
SIGNATURE:	/Brent R. Bellows/
DATE SIGNED:	08/22/2018
Total Attachments: 5	
source=12020-009P1_Executed_Assignment#page1.tif	
source=12020-009P1_Executed_Assignment#page2.tif	
source=12020-009P1_Executed_Assignment#page3.tif	
source=12020-009P1_Executed_Assignment#page4.tif	

ASSIGNMENT

WHEREAS, we, **Adel Moussa**, of Burlington, MA; and **Jean-Pierre Sommadossi**, of Boston, MA; have invented certain new and useful inventions disclosed in a U.S. provisional patent application “**NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS**”, which is identified in the United States Patent and Trademark Office by Application No. 62/453,437, filed on **February 1, 2017** (collectively “Application”), and for which an application for Letters Patent in the United States and other foreign jurisdictions claiming priority to the said provisional application will be made.

WHEREAS, **Atea Pharmaceuticals, Inc.** (“Assignee”), a business entity organized and existing under the laws of the State of Delaware, and having its principal offices at 2 Avery Street, Boston, MA 02111, is entitled to the ownership of this invention and all applications describing this invention by virtue of the employment of the inventors, and thus desires to acquire the entire right, title, and interest in and to said inventions, improvements and applications and in and to the Letters.

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, we, **Adel Moussa** and **Jean-Pierre Sommadossi**, by these presents do sell, assign, and transfer to **Atea Pharmaceuticals, Inc.** the full, exclusive, and entire right, title, and interest in and to said Application, and in and to all inventions and improvements disclosed and described in said Application, as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said Application.

For the same consideration, we, by these presents, do sell, assign, and transfer to **Atea Pharmaceuticals, Inc.** the full, exclusive, and entire right, title, and interest in and to any U.S. nonprovisional or foreign application or any other applications that correspond to or claim priority to said Application, in whole or in part, and to any Letters Patent and similar protective rights granted on said U.S. nonprovisional or foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters


Patent which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said U.S. nonprovisional or foreign applications to be filed and issued in the name of **Atea Pharmaceuticals, Inc.** or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, we do hereby agree that we and our executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to us relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to the said improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby assigned and conveyed, or intended so to be.


AND, furthermore we covenant and agree with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us.

The Assignors agree that this general assignment is effective from the 1st day of February 2017.

IN TESTIMONY, WHEREOF, the Assignor and Assignee set hereunto their hands and seal this date.




Adel Moussa



Authorized Signatory
Atea Pharmaceuticals, Inc.

IN TESTIMONY, WHEREOF, the Assignor and Assignee set hereunto their hands and seal this date.

A handwritten signature in black ink, appearing to read 'JP Sommadossi', is written over a horizontal dotted line.

Jean-Pierre Sommadossi

A horizontal dotted line, intended for a signature, is positioned above the authorized signatory text.

**Authorized Signatory
Atea Pharmaceuticals, Inc.**

IN TESTIMONY, WHEREOF, the Assignor and Assignee set hereunto their hands and seal this date.

.....

Adel Moussa



Authorized Signatory
Atea Pharmaceuticals, Inc.